Cleveland BioLabs, Inc.  

(Public, NASDAQ:CBLI)   Watch this stock  
Find more results for CBLI
3.56
0.00 (0.00%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.07 - 16.20
Open     -
Vol / Avg. 0.00/83,895.00
Mkt cap 12.21M
P/E 10.27
Div/yield     -
EPS 0.35
Shares 3.44M
Beta 1.86
Inst. own 5%
May 6, 2015
Q1 2015 Cleveland Biolabs Inc Earnings Release (Estimated) Add to calendar
Feb 24, 2015
Q4 2014 Cleveland Biolabs Inc Earnings Call
Feb 24, 2015
Q4 2014 Cleveland Biolabs Inc Earnings Release
Feb 10, 2015
Cleveland Biolabs Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 768.38% 0.96%
Operating margin 773.50% -5.82%
EBITD margin - -353.19%
Return on average assets 384.63% 0.29%
Return on average equity - -
Employees 33 -
CDP Score - -

Address

73 High St
BUFFALO, NY 14203-1149
United States - Map
+1-716-8496810 (Phone)
+1-716-8496820 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company�s programs are focused on the implementation of novel pharmacological approaches to control cell death. Its proprietary drug candidates act through mechanisms and targets to kill cancer and protect healthy cells. The Company�s lead product candidates include Entolimod, which is designed for biodefense indication and as an oncology drug, and Curaxin CBL0137, a lead oncology product candidate. The Company�s products include Entolimod (CBLB502) Biodefense, Entolimod (CBLB502) Oncology, CBLB612, CBLC102 and CBLC137, Revercom, Mobilan, Arkil, Antimycon and Xenomycins. The Company�s subsidiaries include Incuron, LLC, which develops product candidates CBL0102 and CBL0137 for oncology indications; and Panacela, which develops new preclinical product candidates, primarily focused in oncology.

Officers and directors

Yakov N. Kogan Ph.D. Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Alexander Polinsky Ph.D. Independent Vice Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
C. Neil Lyons CPA Chief Financial Officer
Age: 58
Bio & Compensation  - Reuters
Andrei V. Gudkov Ph.D. Chief Scientific Officer, Director
Age: 58
Bio & Compensation  - Reuters
James J. Antal CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Julia R. Brown Independent Director
Age: 67
Bio & Compensation  - Reuters
Daniel F. Hoth M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
Elena Nikolaevna Kasimova Independent Director
Age: 54
Bio & Compensation  - Reuters
Richard S. McGowan Esq., J.D. Independent Director
Age: 61
Bio & Compensation  - Reuters